Charles Bennett to United States
This is a "connection" page, showing publications Charles Bennett has written about United States.
Connection Strength
4.080
-
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions. Cancer Treat Res. 2022; 184:41-51.
Score: 0.081
-
Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration. Cancer Treat Res. 2022; 184:61-73.
Score: 0.081
-
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions. Cancer Treat Res. 2022; 184:75-85.
Score: 0.081
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.077
-
Contemporary Clinical Trials Office: Doing More With Less. JCO Oncol Pract. 2021 01; 17(1):1-2.
Score: 0.076
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.076
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.073
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.072
-
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
Score: 0.069
-
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. Cancer Med. 2019 05; 8(5):2233-2240.
Score: 0.067
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.067
-
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.
Score: 0.067
-
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs. 2018 Nov; 78(17):1777-1781.
Score: 0.065
-
Fluoroquinolone-associated suicide. Eur J Intern Med. 2018 09; 55:e21-e22.
Score: 0.064
-
Editorial Comment. Urology. 2018 08; 118:125-126.
Score: 0.063
-
Biosimilars-Curb Your Enthusiasm. JAMA Oncol. 2017 11 01; 3(11):1467-1468.
Score: 0.061
-
Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
Score: 0.060
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.059
-
Why California's Proposition 61 Was a Bad Idea. Am J Med. 2017 08; 130(8):882-884.
Score: 0.059
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.059
-
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
Score: 0.058
-
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. J Clin Oncol. 2016 12 20; 34(36):4320-4322.
Score: 0.057
-
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf. 2016 Aug; 15(8):1003-11.
Score: 0.056
-
Time course and predictors of use of erectile dysfunction treatment in a Veterans Affairs medical center. Int J Impot Res. 2016 Sep; 28(5):167-71.
Score: 0.055
-
Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis. PLoS One. 2016; 11(5):e0155259.
Score: 0.055
-
Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer. Breast Cancer Res Treat. 2016 05; 157(1):193-200.
Score: 0.055
-
FDA Approval of Extended-Release Oxycodone for Children With Severe Pain. Pediatrics. 2016 05; 137(5).
Score: 0.055
-
Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016 04; 22(4):242-8.
Score: 0.055
-
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016 May; 44:61-4.
Score: 0.055
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.054
-
Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Expert Opin Drug Saf. 2015; 14(11):1653-60.
Score: 0.053
-
"Right-to-Try" Legislation: Progress or Peril? J Clin Oncol. 2015 Aug 20; 33(24):2597-9.
Score: 0.052
-
Vision insurance, eye care visits, and vision impairment among working-age adults in the United States. JAMA Ophthalmol. 2013 Apr; 131(4):499-506.
Score: 0.044
-
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):905-7.
Score: 0.043
-
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8(6):e158-67.
Score: 0.043
-
Pharmaceutical fraud and abuse in the United States, 1996-2010. Arch Intern Med. 2011 Sep 12; 171(16):1503-6.
Score: 0.040
-
Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf. 2011 Jul; 10(4):521-8.
Score: 0.039
-
Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med. 2011 Apr 25; 171(8):785-7.
Score: 0.039
-
The excessive cost of early stage bladder cancer care: are providers really to blame? Cancer. 2010 Aug 01; 116(15):3530-2.
Score: 0.037
-
Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. J Clin Oncol. 2010 May 20; 28(15):2571-6.
Score: 0.036
-
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar; 24(3):260-8.
Score: 0.036
-
Racial variations in care and outcomes for inpatient HIV-related pneumocystis pneumonia. J Health Care Poor Underserved. 2010 Feb; 21(1):318-33.
Score: 0.036
-
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009 Sep 10; 27(26):4398-405.
Score: 0.034
-
Partnering to promote equality in cancer care. Soc Work Public Health. 2009 Jul-Aug; 24(4):355-9.
Score: 0.034
-
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008 Dec; 9(12):1166-72.
Score: 0.033
-
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008 Mar 24; 168(6):632-42.
Score: 0.031
-
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. Cancer Treat Res. 2008; 140:235-51.
Score: 0.031
-
The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol. 2007 Aug 20; 25(24):3567-9.
Score: 0.030
-
Process evaluation in an intervention designed to improve rates of colorectal cancer screening in a VA medical center. Health Promot Pract. 2007 Jul; 8(3):273-81.
Score: 0.030
-
Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project. Semin Thromb Hemost. 2007 Jun; 33(4):365-72.
Score: 0.030
-
Cost considerations in the management of cancer in the older patient. Oncology (Williston Park). 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim.
Score: 0.030
-
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007 May 28; 167(10):1041-9.
Score: 0.030
-
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007 Apr; 12(4):478-83.
Score: 0.029
-
Local perspective of the impact of the HIPAA privacy rule on research. Cancer. 2006 Jan 15; 106(2):474-9.
Score: 0.027
-
Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. J Clin Oncol. 2005 Dec 01; 23(34):8877-83.
Score: 0.027
-
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol. 2005 Dec 01; 23(34):8894-905.
Score: 0.027
-
Relation between literacy and HIV treatment knowledge among patients on HAART regimens. AIDS Care. 2005 Oct; 17(7):863-73.
Score: 0.026
-
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7.
Score: 0.026
-
Health care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial. J Clin Oncol. 2005 Mar 01; 23(7):1548-54.
Score: 0.025
-
Delays in suspicion and isolation among hospitalized persons with pulmonary tuberculosis at public and private US hospitals during 1996 to 1999. Chest. 2005 Jan; 127(1):205-12.
Score: 0.025
-
Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Pract Res Clin Haematol. 2005; 18(3):449-54.
Score: 0.025
-
Health literacy and patient knowledge in a Southern US HIV clinic. Int J STD AIDS. 2004 Nov; 15(11):747-52.
Score: 0.025
-
Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect. 2004 Jun; 7(2):115-25.
Score: 0.024
-
Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Feb 01; 35(2):120-5.
Score: 0.024
-
US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. Chest. 2004 Feb; 125(2):548-56.
Score: 0.024
-
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004 Feb; 35(2):533-7.
Score: 0.023
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
Score: 0.023
-
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003 Oct 15; 21(20):3859-66.
Score: 0.023
-
Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol. 2003 Mar 01; 21(5):937-41.
Score: 0.022
-
Medicare Spending on Drugs With Accelerated Approval. Ann Intern Med. 2022 07; 175(7):938-944.
Score: 0.021
-
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias. J Clin Epidemiol. 2022 08; 148:193-195.
Score: 0.020
-
Clinical trials: are they a good buy? J Clin Oncol. 2001 Dec 01; 19(23):4330-9.
Score: 0.020
-
Hospital measures for prevention of tuberculosis transmission in U.S. cities with and without previous nosocomial tuberculosis outbreaks. Ann Intern Med. 2000 Sep 19; 133(6):486.
Score: 0.019
-
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000 Aug; 18(15):2805-10.
Score: 0.018
-
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et al. Expert Opin Drug Saf. 2020 08; 19(8):1057-1058.
Score: 0.018
-
Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1999 Nov; 17(11):3676-81.
Score: 0.018
-
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol. 1999 Nov; 10(11):1355-9.
Score: 0.018
-
Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999 Oct 20; 282(15):1453-7.
Score: 0.017
-
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. Expert Opin Drug Saf. 2019 Nov; 18(11):1055-1063.
Score: 0.017
-
Racial variation in the use of laparoscopic cholecystectomy in the Department of Veterans Affairs medical system. J Am Coll Surg. 1999 Jun; 188(6):604-22.
Score: 0.017
-
The relation between physician experience and patterns of care for patients with AIDS-related Pneumocystis carinii pneumonia: results from a survey of 1,500 physicians in the United States. Chest. 1999 Jun; 115(6):1563-9.
Score: 0.017
-
Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol. 1999 Apr; 26(2 Suppl 7):102-7.
Score: 0.017
-
Diffusion of laparoscopic cholecystectomy in the Veterans Affairs health care system, 1991-1995. Eff Clin Pract. 1999 Mar-Apr; 2(2):49-55.
Score: 0.017
-
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 1):40-5.
Score: 0.017
-
Identifying providers of care to individuals with human immunodeficiency virus for a mail survey using a prescription tracking database. J Clin Epidemiol. 1999 Feb; 52(2):147-50.
Score: 0.017
-
A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol. 2019 Oct; 37(10):2099-2108.
Score: 0.017
-
Growth of oncology physician practice management companies. Cancer Invest. 1999; 17(5):362-70.
Score: 0.017
-
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest. 1999; 17(8):559-65.
Score: 0.017
-
Cancer insurance policies in Japan and the United States. West J Med. 1998 Jan; 168(1):17-22.
Score: 0.015
-
Gender differences in care for acquired immunodeficiency syndrome-related Pneumocystis carinii pneumonia. Womens Health Issues. 1998 Jan-Feb; 8(1):45-52.
Score: 0.015
-
Health economics in the treatment of colorectal cancer. Cancer Invest. 1998; 16(8):582-7.
Score: 0.015
-
Visual coping scenarios to facilitate discussion of coping responses with impoverished women at risk for AIDS. J Psychosoc Nurs Ment Health Serv. 1997 Aug; 35(8):17-23.
Score: 0.015
-
Variations in medical care for HIV-related Pneumocystis carinii pneumonia: a comparison of process and outcome at two hospitals. Chest. 1997 Aug; 112(2):398-405.
Score: 0.015
-
Predicting in-hospital mortality of patients with AIDS-related Pneumocystis carinii pneumonia: an example of hierarchically optimal classification tree analysis. Stat Med. 1997 Jul 15; 16(13):1451-63.
Score: 0.015
-
Gender differences in early suspicion of tuberculosis in hospitalized, high-risk patients during 4 epidemic years, 1987 to 1990. Infect Control Hosp Epidemiol. 1997 Apr; 18(4):237-43.
Score: 0.015
-
Health care economics and bone marrow transplantation. Cancer Treat Res. 1997; 77:377-99.
Score: 0.014
-
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest. 1997; 15(3):227-36.
Score: 0.014
-
The effect of ethnicity on ICU use and DNR orders in hospitalized AIDS patients. J Clin Ethics. 1997; 8(2):150-7.
Score: 0.014
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.014
-
Geographic variation in the management and outcome of patients with AIDS-related Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15; 13(5):408-15.
Score: 0.014
-
U.S. hospital care for HIV-infected persons and the role of public, private, and Veterans Administration hospitals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15; 13(5):416-21.
Score: 0.014
-
Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: A competing-risk model. Maturitas. 2017 Jan; 95:42-49.
Score: 0.014
-
Patterns of care for HIV-related Pneumocystis carinii pneumonia in a university medical program: a case study. Clin Perform Qual Health Care. 1996 Oct-Dec; 4(4):186-9.
Score: 0.014
-
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1996 Sep; 14(9):2511-20.
Score: 0.014
-
Western impressions of the Hong Kong health care system. West J Med. 1996 Jul-Aug; 165(1-2):37-42.
Score: 0.014
-
Assessing Colorectal Cancer Screening Adherence of Medicare Fee-for-Service Beneficiaries Age 76 to 95 Years. J Oncol Pract. 2016 06; 12(6):e670-80.
Score: 0.014
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
Score: 0.014
-
Performance measurement in prostate cancer care: beyond report cards. Urology. 1996 Mar; 47(3):356-65.
Score: 0.014
-
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol. 1995 Sep; 13(9):2457-63.
Score: 0.013
-
Multi-city study of quality of care for HIV-related Pneumocystis carinii pneumonia: successfully collecting highly sensitive information. Clin Perform Qual Health Care. 1995 Jul-Sep; 3(3):140-6.
Score: 0.013
-
Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Clin Perform Qual Health Care. 1995 Jul-Sep; 3(3):156-64.
Score: 0.013
-
The learning curve for AIDS-related Pneumocystis carinii pneumonia: experience from 3,981 cases in Veterans Affairs Hospitals 1987-1991. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 01; 8(4):373-8.
Score: 0.013
-
Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2015 01; 11(1):e59-65.
Score: 0.012
-
Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med. 2014 Mar-Apr; 12(2):121-7.
Score: 0.012
-
Improved outcomes in intensive care units for AIDS-related Pneumocystis carinii pneumonia: 1987-1991. J Acquir Immune Defic Syndr (1988). 1993 Dec; 6(12):1319-21.
Score: 0.012
-
Angiotensin receptor blockers: are they related to lung cancer? J Hypertens. 2013 Aug; 31(8):1669-75.
Score: 0.011
-
Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J Clin Pharmacol. 2013 Jul; 53(7):773-8.
Score: 0.011
-
Does experience improve hospital performance in treating patients with AIDS? Health Policy. 1993 Apr; 24(1):35-43.
Score: 0.011
-
Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention. J Clin Oncol. 2012 Nov 10; 30(32):3947-52.
Score: 0.011
-
Medical care costs of intravenous drug users with AIDS in Brooklyn. J Acquir Immune Defic Syndr (1988). 1992; 5(1):1-6.
Score: 0.010
-
Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother. 2010 Apr; 54(4):1534-40.
Score: 0.009
-
AIDS care needs wider QA effort. QA Rev. 1989 Dec; 1(5):6.
Score: 0.009
-
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology. 2010 Mar; 75(3):623-9.
Score: 0.009
-
The relation between hospital experience and in-hospital mortality for patients with AIDS-related PCP. JAMA. 1989 May 26; 261(20):2975-9.
Score: 0.009
-
Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009 Jan; 249(1):63-71.
Score: 0.008
-
Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
Score: 0.008
-
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf. 2009; 32(2):147-58.
Score: 0.008
-
Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007 May 09; 297(18):1992-2000.
Score: 0.007
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20; 25(12):1596-605.
Score: 0.007
-
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007 Feb 07; 99(3):196-205.
Score: 0.007
-
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604.
Score: 0.007
-
A qualitative study of literacy and patient response to HIV medication adherence questionnaires. J Health Commun. 2005 Sep; 10(6):509-17.
Score: 0.007
-
Development of a brief survey on colon cancer screening knowledge and attitudes among veterans. Prev Chronic Dis. 2005 Apr; 2(2):A11.
Score: 0.006
-
HIV-related pneumonia care in older patients hospitalized in the early HAART era. AIDS Patient Care STDS. 2004 Feb; 18(2):99-107.
Score: 0.006
-
Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology. 2003 Jan; 61(1):172-8.
Score: 0.005
-
Nosocomial tuberculosis prevention measures among two groups of US hospitals, 1992 to 1996. Chest. 2000 Feb; 117(2):380-4.
Score: 0.004
-
QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Williston Park). 1999 Jun; 13(6):823-32; discussion 835-8.
Score: 0.004
-
Variations in intensive care unit utilization for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia: importance of hospital characteristics and geographic location. Crit Care Med. 1998 Apr; 26(4):668-75.
Score: 0.004
-
Approaches to prostate cancer by managed care organizations. Urology. 1997 Jul; 50(1):79-86.
Score: 0.004
-
Predictors of resource utilization for hospitalized patients with Pneumocystis carinii pneumonia (PCP): a summary of effects from the multi-city study of quality of PCP care. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 01; 12(4):379-85.
Score: 0.003
-
Self-perceived unmet health care needs of persons enrolled in HIV care. J Community Health. 1996 Jun; 21(3):183-98.
Score: 0.003
-
The impact of housing status on health care utilization among persons with HIV disease. J Health Care Poor Underserved. 1996; 7(1):36-49.
Score: 0.003
-
AIDS-related knowledge, perceptions, and behaviors among impoverished minority women. Am J Public Health. 1993 Jan; 83(1):65-71.
Score: 0.003